Introduction The University of Wollongong, situated in the seaside town of Wollongong in New South Wales, is a public research university approximately 80 kilometers south of Sydney. |
Disease Domain | Count |
---|---|
Infectious Diseases | 3 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 3 |
Top 5 Target | Count |
---|---|
toxA x toxB | 1 |
Target |
Mechanism toxA inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism Cell wall modulators |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism Bacterial biofilms inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date04 Sep 2024 |
Sponsor / Collaborator |
Start Date26 Jun 2024 |
Sponsor / Collaborator |
Start Date17 Jun 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
AMINOPIP2-ceftazidime12 | Pseudomonas aeruginosa infection More | Preclinical |
AVX-13616 | Staphylococcal Infections More | Preclinical |
6-a ( toxA x toxB ) | Clostridium difficile infection More | Preclinical |
JGNBB-32 ( CRF receptor ) | - | Pending |